Lake Street Cuts Pelthos Therapeutics Price Target to $40
Lake Street maintained its Buy rating on Pelthos Therapeutics while lowering the stock’s price target to $40.00 per share from $50.00.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Benzinga’s analyst-ratings section reports that Lake Street maintained its Buy rating on Pelthos Therapeutics.
At the same time, the firm reduced its price target for the company’s shares to $40.00 per share from the previous $50.00.
why it matters
Keeping a Buy rating while lowering the target price signals a change in the analyst’s valuation assessment and may affect market sentiment toward PTHS shares.
instruments
sources
- Pelthos Therapeutics Price Target Cut to $40.00/Share From $50.00 by Lake Street — Newsmetry API, 12 October 2026 at 20:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗